What is Tepezza (teprotumumab-trbw) for?
Buy Tepezza (teprotumumab-trbw). Tepezza (teprotumumab-trbw) is a treatment for thyroid eye disease (TED). It’s also known as Grave’s eye disease. It works by blocking the insulin-like growth factor-1 receptor (IGF-1R).
It comes as an intravenous powder for injection. Each vial contains 500 mg of teprotumumab-trbw.
How does Tepezza (teprotumumab-trbw) work?
TED is an autoimmune disease. It makes the thyroid gland swell, causing eye problems. These include bulging eyes, double vision, and pain.
The IGF-1R plays a part in TED. Teprotumumab-trbw blocks it. This reduces swelling and improves symptoms.
Where has Tepezza (teprotumumab-trbw) been approved?
Tepezza (teprotumumab-trbw) was approved by:
- The Food and Drug Administration (FDA), USA, on January 21, 2020.
It’s the first medicine for TED. The FDA gave it special designations for fast approval.
In December 2016, the European Medicines Agency (EMA) also approved it. This was without needing more data.
It might be approved in other places too. If you’re unsure, contact our support team.
How is Tepezza (teprotumumab-trbw) taken?
The dosage is:
- 10 mg/kg body weight for the first dose
- Then 20 mg/kg body weight every three weeks for 7 more doses
It’s given as an intravenous infusion into a vein.
For full details, see the official prescribing information. Note: Always talk to your doctor about your dosage.
Are there any known adverse reactions or side effects of Tepezza (teprotumumab-trbw)?
Common adverse reactions
Common side effects include:
- Muscle cramps or spasms
- Nausea
- Hair loss
- Diarrhea
- Feeling tired
- High blood sugar
- Hearing problems
- Taste changes
- Headache
- Dry skin
Use in a specific population
Tepezza can harm a fetus. It’s advised to avoid pregnancy and breastfeeding.
For a full list of side effects, see the official prescribing information.